ConductScience.org, home

Paper39031809

Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.

Wu Y and 11 others. Adv Sci (Weinh), 2024. Cited by 68 papers, by iCite.

Cite this record

ConductScience Library. Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases. Papers, record 39031809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39031809

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.
PubMed
Journal
Adv Sci (Weinh)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
68
iCite
Relative citation ratio, by iCite
14.0, provisional
iCite
Revised in PubMed
2026-03-10
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wu YYue
2Li XXin
3Fu XXueyu
4Huang XXiaomin
5Zhang SShenrong
6Zhao NNan
7Ma XXiaowei
8Saiding QQimanguli
9Yang MMei
10Tao WWei
11Zhou XXingtao
12Huang JJinhaihttps://orcid.org/0000-0001-9952-3175

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug Delivery SystemsMajor topic
Eye DiseasesMajor topic
Humans
Nanotechnology
Posterior Eye Segment
Animals
Nanomedicine
Nanostructures
Diabetic Retinopathy

Source PubMed

Download CSV of topics

Grants12

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
82271048National Nature Science Foundation of ChinaPubMed
61905130National Nature Science Foundation of ChinaPubMed
23ZR1409500Project of Shanghai Science and TechnologyPubMed
23XD1420500Project of Shanghai Science and TechnologyPubMed
23S11900200Project of Shanghai Science and TechnologyPubMed
22S11900200Project of Shanghai Science and TechnologyPubMed
2021318EYE & ENT Hospital of Fudan University High-level Talents ProgramPubMed
yg2023-06Medical Engineering fund of Fudan UniversityPubMed
yg2023-206Medical Engineering fund of Fudan UniversityPubMed
2018M640145Postdoctoral Science Foundation of ChinaPubMed
2019T120106Postdoctoral Science Foundation of ChinaPubMed
Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning;PubMed

Source PubMed

Download CSV of grants

References193

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131884933Nano-Based Drug Delivery System: Recent Strategies for the Treatment of Ocular Disease and Future Perspective.Recent Pat Drug Deliv Formul2019https://conductscience.org/library/papers/31884933PubMed
219689343Nanocarriers in ocular drug delivery: an update review.Curr Pharm Des2009https://conductscience.org/library/papers/19689343PubMed
339031809Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.Adv Sci (Weinh)2024https://conductscience.org/library/papers/39031809PubMed
434923749The blood-retina barrier in health and disease.FEBS J2023https://conductscience.org/library/papers/34923749PubMed
529452593A review on biosynthesis of silver nanoparticles and their biocidal properties.J Nanobiotechnology2018https://conductscience.org/library/papers/29452593PubMed
636871144MMP9-Responsive Graphene Oxide Quantum Dot-Based Nano-in-Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization.Small2023https://conductscience.org/library/papers/36871144PubMed
718275911Current and future ophthalmic drug delivery systems. A shift to the posterior segment.Drug Discov Today2008https://conductscience.org/library/papers/18275911PubMed
811276432Fibroblast growth factors.Genome Biol2001https://conductscience.org/library/papers/11276432PubMed
936461689Functional Carbon Quantum Dots for Ocular Imaging and Therapeutic Applications.Small2023https://conductscience.org/library/papers/36461689PubMed
1023584393Extracellular vesicles: biology and emerging therapeutic opportunities.Nat Rev Drug Discov2013https://conductscience.org/library/papers/23584393PubMed
1130849371VEGF in Signaling and Disease: Beyond Discovery and Development.Cell2019https://conductscience.org/library/papers/30849371PubMed
1234527806Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy.Adv Ther (Weinh)2021https://conductscience.org/library/papers/34527806PubMed
1321884302Macrophage polarization in the maculae of age-related macular degeneration: a pilot study.Pathol Int2011https://conductscience.org/library/papers/21884302PubMed
1430583149Mussel-inspired injectable hydrogel and its counterpart for actuating proliferation and neuronal differentiation of retinal progenitor cells.Biomaterials2019https://conductscience.org/library/papers/30583149PubMed
1526709963Quantum dot as probe for disease diagnosis and monitoring.Biotechnol J2016https://conductscience.org/library/papers/26709963PubMed
1629637733Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment.J Biomed Mater Res A2018https://conductscience.org/library/papers/29637733PubMed
1730257317Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy.Biomed Pharmacother2018https://conductscience.org/library/papers/30257317PubMed
1833669093Beneficial Effect of Tempol, a Membrane-Permeable Radical Scavenger, on Inflammation and Osteoarthritis in In Vitro Models.Biomolecules2021https://conductscience.org/library/papers/33669093PubMed
1934041903Graphene Family Nanomaterials in Ocular Applications: Physicochemical Properties and Toxicity.Chem Res Toxicol2021https://conductscience.org/library/papers/34041903PubMed
2030530176Pharmaceutical applications of chitosan.Adv Colloid Interface Sci2019https://conductscience.org/library/papers/30530176PubMed

See all 193 referencesDownload CSV of references

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 68 citations.

PMIDTitleJournalYearIn PapersSource
42898393Application of nanozyme-based drug delivery systems in the treatment of ROS-related ophthalmic diseases.Int J Pharm X2026https://conductscience.org/library/papers/42898393PubMed
42654098Hydrogel-Based Ocular Drug Delivery Systems: A Bibliometric and Visualization Analysis of Research Trends and Hotspots (1991-2025).Pharmaceutics2026https://conductscience.org/library/papers/42654098PubMed
42640395Exosomes in the treatment of age-related ophthalmic diseases: an updated review.Int Ophthalmol2026https://conductscience.org/library/papers/42640395PubMed
42434121Nanomaterial-enabled delivery of plant-derived bioactive metabolites for diabetic retinopathy: from evidence appraisal to preclinical translation.Front Pharmacol2026https://conductscience.org/library/papers/42434121PubMed
42415853Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence.MedComm (2020)2026https://conductscience.org/library/papers/42415853PubMed
42298628Dual-targeting VEGF and TNF-α with bispecific antibody eyedrops for synergistic treatment of uveitis.J Nanobiotechnology2026https://conductscience.org/library/papers/42298628PubMed
42278630Special Issue "Integrated Approaches, Molecular Mechanisms and Therapies in Ocular Surface Diseases".Int J Mol Sci2026https://conductscience.org/library/papers/42278630PubMed
42195365Nanocarrier-Based Ocular Drug Delivery Systems for Retinal Diseases: Therapeutic Potential.Life (Basel)2026https://conductscience.org/library/papers/42195365PubMed
42100289Relationship between choroidal thickness changes and macrophage polarization in high myopia.Front Med (Lausanne)2026https://conductscience.org/library/papers/42100289PubMed
42090084Extracellular vesicles in ophthalmology: innovations in diagnosis, therapy, and drug delivery.Mol Biol Rep2026https://conductscience.org/library/papers/42090084PubMed
42042291Advances and Challenges in Tissue Engineering: Biomaterials, Cellular Strategies, and Clinical Applications.J Funct Biomater2026https://conductscience.org/library/papers/42042291PubMed
42007156
The impact of anti-vascular endothelial growth factor therapy on the activation status of retinal macrophages/microglia in patients with diabetic retinopathy and familial exudative vitreoretinopathy and its association with treatment response.
Am J Transl Res2026https://conductscience.org/library/papers/42007156PubMed
41987176A sequential dual-drug delivery system for multi-target inhibition of subretinal fibrosis.J Nanobiotechnology2026https://conductscience.org/library/papers/41987176PubMed
41976211Engineering Strategies of Colloidal Drug Delivery Systems, a Rising Star in Ocular Neovascular Diseases.Molecules2026https://conductscience.org/library/papers/41976211PubMed
41939725Engineered small extracellular vesicles as bioactive materials: Integrating engineering strategies for cargo loading and targeted delivery systems.Bioact Mater2026https://conductscience.org/library/papers/41939725PubMed
41858590The Cross-Species Implantable ATP Battery Inspired by Photosynthesis for Application in Diseases.Int J Nanomedicine2026https://conductscience.org/library/papers/41858590PubMed
41677384Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics.Adv Sci (Weinh)2026https://conductscience.org/library/papers/41677384PubMed
41660128ROS-responsive transmembrane peptide-antibody conjugate eyedrops for the non-invasive treatment of choroidoretinopathy.Mater Today Bio2026https://conductscience.org/library/papers/41660128PubMed
41604030Nanotherapeutic potential in glaucoma associated ocular cancers.Discov Oncol2026https://conductscience.org/library/papers/41604030PubMed
41549124Diabetes and its complications: molecular mechanisms, prevention and treatment.Signal Transduct Target Ther2026https://conductscience.org/library/papers/41549124PubMed

See all 45 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
VEGFA7422PubTator's text mininghttps://conductscience.org/library/genes/7422

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39031809

GET https://conductscience.org/api/papers/v1/39031809/references?page=2